Incyte Corporation (NASDAQ:INCY) released topline results from its pivotal Phase 3 STOP-HS clinical trial program of ...
Both Palmyra track teams beat Lower Dauphin in the season opener on Tuesday. The boys won 117-32, while the girls earned a ...
Incyte's revenues continues to grow, with full-year 2024 revenues reaching $4.2 billion, driven by JAKAFI and OPZELURA. Click ...
尼妥珠单抗为百泰生物药业有限公司研制的一种抗EGFR的单克隆抗体。该药于2008年在中国上市，目前已在全球30个国家获批上市，在7个国家获批食管癌适应症。多项临床研究显示，使用尼妥珠单抗治疗食管癌患者是安全、有效的选择。
GENFIT completes a royalty financing of up to €185 million with HCRx after unanimous OCEANE bondholder approval, triggering a €130 million ...
Market Index on MSN2 天
Evening Wrap: ASX 200 gains as coal stocks pop on strong NHC result, copper miners rally ...The S&P/ASX 200 closed 6.3 points higher, up 0.08%. Coal stocks popped on a well received half-year results release from New ...
Market Index on MSN1 天
Evening Wrap: ASX 200 slides despite gains in uranium, critical metals, and battery stocks ...The S&P/ASX 200 closed 32.1 points lower, down 0.41%. Uranium stocks saw another steady day of gains today as the uranium ...
Warner Bros. Discovery Inc. Series A $10.92 0.53 5.10% ...
Objectives This study was conducted to determine the predictors of sexual dysfunction and quality of life (QOL) in patients with type 2 diabetes (T2D). Sexual dysfunction is a long-term consequence of ...
A new analysis out of England shows a considerable level of uncertainty among adults who think they could have long COVID, as ...
截至2025年3月18日 ...
研究结论与讨论：对于心脏受累的 AL 淀粉样变患者，包括 Ⅲb 期患者，基于达雷妥尤单抗的治疗方案在血液学缓解、心脏反应和无进展生存期方面具有优势，且耐受性与硼替佐米相当。即使是硼替佐米难治的患者，转换为达雷妥尤单抗治疗后也能获得临床益处，这表明达雷妥尤单抗在挽救治疗中具有重要作用。不过，该研究存在样本量小和回顾性研究设计的局限性，还需要更大规模的前瞻性试验进一步验证这些结果。
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈